Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RiboTargets: Targeting mRNA rationally

Targeting mRNA for the treatment of infectious diseases is not a new concept. But previous attempts have failed through lack of specificity to appropriate binding sites. RiboTargets Ltd. believes it has solved that problem with technology focused on the interactions between RNA and its regulatory proteins, such as those that attach ribosomes before translation, or move RNA around the cell. The company also has developed three-dimensional computer simulations

Read the full 681 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers